December 28, 2023
June 2, 2023
After years of litigation, the Hess Corporation agreed to settle hundreds of asbestos exposure lawsuits filed on the island of St. Croix. The company will establish a $106 million trust for victims, their surviving family members, and those that may be diagnosed in the future. A Hess-owned oil refinery operated on the island from 1965 to 1998, and exposed workers and people staying on the island to asbestos and benzene. Hess will provide $90 million in compensation for mesothelioma and other claimants who have filed for compensation. An additional $15 million is being set aside to benefit those who may be […]
March 14, 2023
CIMAvax-EGF is a new lung cancer treatment that “harnesses the body’s immune system to fight lung cancer.” They began testing the drug in 2017; another trial is testing the drug for the prevention of lung cancer in patients who are at high risk. CIMAvax-EGF blocks a certain protein (epidermal growth factor (EGF)) that cancer cells need to grow. The drug works by starving the cancer cells by preventing EGF from attaching to the cell. If the cancer cell cannot multiply, it dies. They have treated more than 5,000 lung cancer patients so far with this unique immunotherapy. Several international studies […]
January 10, 2023
Base editing is a revolutionary technology that has the potential to revolutionize the treatment of mesothelioma. This technology allows scientists to make precise, targeted changes to a patient’s genetic code, without introducing any foreign DNA into the patient’s body. This technology has the potential to be used to treat cancer and other genetic diseases. A young patient with leukemia is now clear of the cancer after base editing therapy. In the future, base editing could be used to create personalized treatments for mesothelioma. By analyzing a patient’s genetic code, doctors could determine the best approach to treating their mesothelioma. This […]
September 27, 2022
Verismo Therapeutics announced that is has received clearance of its new drug for ovarian cancer, cholangiocarcinoma, and, mesothelioma from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase 1 clinical trial of SynKIR-110. The first human trials are set to start soon. They will “address several areas of high unmet medical need.” The five-year survival rates are 49.7% for ovarian cancer, 30% for cholangiocarcinoma and 10% for mesothelioma. The FDA’s clearance of the new drug represents a new for mesothelioma treatments and innovative research. Verismo plans to begin enrolling patients in the first quarter of 2023 at […]
April 5, 2022
Whether it is primary exposure due to working directly with the dangerous material or secondary exposure suffered by friends and family, contact with asbestos fibers can lead to devastating, deadly conditions. Unfortunately, it is not uncommon for medical professionals to incorrectly diagnose mesothelioma, asbestosis or lung cancer when early symptoms become apparent. While every situation is unique, there are numerous factors that can dramatically impact the speed and accuracy of a medical diagnosis for mesothelioma, including: Symptom overlap: Unfortunately, mesothelioma shares numerous symptoms with other lung conditions that range in seriousness. This can make it challenging for a medical professional […]
February 18, 2022
The stereotype of a mesothelioma patient is an older male who plied a trade over decades that exposed him to asbestos. In fact, many women receive these life-changing diagnoses. The disease does not discriminate. A recent study reveals the different dynamics between the genders, their specific needs, and how they deal with an uncertain and [...]
February 18, 2022
A cure for malignant mesothelioma remains elusive and is considered one of the most challenging to measure with CT scans due to characteristically complex growth patterns. However, scientists based in Scotland – a country near the top of mesothelioma incidence rates – may have found a way to radically change treating the life-changing, deadly disease. [...]
February 18, 2022
Media coverage in 2020 surrounded a particular virus and the progress made in defeating it. Similarly, new treatments, drug regimens, and cutting-edge and highly successful trials gave a glimmer of hope to those suffering from mesothelioma, not to mention their family members. Some of the more prominent stories included: The FDA approves Keytruda Pembrolizumab, an [...]
February 18, 2022
ERROR While mesothelioma continues to lack a cure, early detection can make a difference in the lives of those suffering from the deadly disease. Those proactive steps present challenges with countless mesothelioma victims diagnosed when tumors have already progressed. Symptoms are often disregarded as run-of-the-mill health issues that don’t require any attention. When it comes [...]
- All
- Arbitration
- Asbestos
- Asbestos-Related Illness
- Benzene
- Brayton Purcell News
- Chemicals and Toxic Substances
- Congress and Politics
- Consumer Safety
- Dangerous Medical Drugs
- Defective Medical Devices
- Elder Abuse
- Emissions-cheating scandal
- Engineered Stone
- Estate Planning
- Firm News
- Legal News
- Medical Malpractice
- Medical News
- Mesothelioma
- Mortgage Fraud
- Occupational Asbestos Exposure
- Product Liability
- Product Recalls
- Safety Tips
- Safety Violations
- Schools
- Tobacco
- Uncategorized
- Veterans’ News
- Whistleblowing
- Workers’ Compensation
- Workers’ Rights
December 28, 2023
June 2, 2023
After years of litigation, the Hess Corporation agreed to settle hundreds of asbestos exposure lawsuits filed on the island of St. Croix. The company will establish a $106 million trust for victims, their surviving family members, and those that may be diagnosed in the future. A Hess-owned oil refinery operated on the island from 1965 to 1998, and exposed workers and people staying on the island to asbestos and benzene. Hess will provide $90 million in compensation for mesothelioma and other claimants who have filed for compensation. An additional $15 million is being set aside to benefit those who may be […]
March 14, 2023
CIMAvax-EGF is a new lung cancer treatment that “harnesses the body’s immune system to fight lung cancer.” They began testing the drug in 2017; another trial is testing the drug for the prevention of lung cancer in patients who are at high risk. CIMAvax-EGF blocks a certain protein (epidermal growth factor (EGF)) that cancer cells need to grow. The drug works by starving the cancer cells by preventing EGF from attaching to the cell. If the cancer cell cannot multiply, it dies. They have treated more than 5,000 lung cancer patients so far with this unique immunotherapy. Several international studies […]
January 10, 2023
Base editing is a revolutionary technology that has the potential to revolutionize the treatment of mesothelioma. This technology allows scientists to make precise, targeted changes to a patient’s genetic code, without introducing any foreign DNA into the patient’s body. This technology has the potential to be used to treat cancer and other genetic diseases. A young patient with leukemia is now clear of the cancer after base editing therapy. In the future, base editing could be used to create personalized treatments for mesothelioma. By analyzing a patient’s genetic code, doctors could determine the best approach to treating their mesothelioma. This […]
September 27, 2022
Verismo Therapeutics announced that is has received clearance of its new drug for ovarian cancer, cholangiocarcinoma, and, mesothelioma from the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase 1 clinical trial of SynKIR-110. The first human trials are set to start soon. They will “address several areas of high unmet medical need.” The five-year survival rates are 49.7% for ovarian cancer, 30% for cholangiocarcinoma and 10% for mesothelioma. The FDA’s clearance of the new drug represents a new for mesothelioma treatments and innovative research. Verismo plans to begin enrolling patients in the first quarter of 2023 at […]
April 5, 2022
Whether it is primary exposure due to working directly with the dangerous material or secondary exposure suffered by friends and family, contact with asbestos fibers can lead to devastating, deadly conditions. Unfortunately, it is not uncommon for medical professionals to incorrectly diagnose mesothelioma, asbestosis or lung cancer when early symptoms become apparent. While every situation is unique, there are numerous factors that can dramatically impact the speed and accuracy of a medical diagnosis for mesothelioma, including: Symptom overlap: Unfortunately, mesothelioma shares numerous symptoms with other lung conditions that range in seriousness. This can make it challenging for a medical professional […]
February 18, 2022
The stereotype of a mesothelioma patient is an older male who plied a trade over decades that exposed him to asbestos. In fact, many women receive these life-changing diagnoses. The disease does not discriminate. A recent study reveals the different dynamics between the genders, their specific needs, and how they deal with an uncertain and [...]
February 18, 2022
A cure for malignant mesothelioma remains elusive and is considered one of the most challenging to measure with CT scans due to characteristically complex growth patterns. However, scientists based in Scotland – a country near the top of mesothelioma incidence rates – may have found a way to radically change treating the life-changing, deadly disease. [...]
February 18, 2022
Media coverage in 2020 surrounded a particular virus and the progress made in defeating it. Similarly, new treatments, drug regimens, and cutting-edge and highly successful trials gave a glimmer of hope to those suffering from mesothelioma, not to mention their family members. Some of the more prominent stories included: The FDA approves Keytruda Pembrolizumab, an [...]
February 18, 2022
ERROR While mesothelioma continues to lack a cure, early detection can make a difference in the lives of those suffering from the deadly disease. Those proactive steps present challenges with countless mesothelioma victims diagnosed when tumors have already progressed. Symptoms are often disregarded as run-of-the-mill health issues that don’t require any attention. When it comes [...]
